BridgeMD
New treatment option for Acute Renal Insufficiency
Official title Evaluation of the Impact of an Alteration of NAD+ Metabolism on the Renal Prognosis of Patients Admitted to Intensive Care (NI-AKI)
ClinicalTrials.gov ID: NCT07203131
What this study is testing
- What it's testing
- Among all patients admitted to intensive care, it is estimated that more than half of them are exposed during their stay to acute renal failure (ARF). Impacting the vital prognosis to short term, the occurrence of renal failure is not without consequences in intensive care survivors, presenting an increased risk of death mainly mediated by an excess risk with regard to chronic kidney disease and/or certain cardiovascular pathologies.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patient, male or female aged over 18,
- Patient admitted to intensive care for a reason with a high risk of ARI: shock, sepsis, cardio-circulatory arrest, post-operative unscheduled...
- Patient with normal renal function on admission,
- Patient affiliated to or beneficiary of a social security scheme,
- Patient having been informed and having given his/her free, informed and written consent
You likely can't join if
- Minor patient,
- History of chronic kidney disease,
- History of kidney transplant,
- Admission for a reason with a low risk of ARI (neuroresuscitation, voluntary drug intoxication with anxiolytics - antidepressants - psychotropic...
- Acute non-infectious respiratory failure, (scheduled surgery other than cardiac surgery)
- Patient hospitalized without consent,
See the full eligibility criteria
- Patient, male or female aged over 18,
- Patient admitted to intensive care for a reason with a high risk of ARI: shock, sepsis, cardio-circulatory arrest, post-operative unscheduled surgery, post-operative cardiac surgery,
- Patient with normal renal function on admission,
- Patient affiliated to or beneficiary of a social security scheme,
- Patient having been informed and having given his/her free, informed and written consent
- Minor patient,
- History of chronic kidney disease,
- History of kidney transplant,
- Admission for a reason with a low risk of ARI (neuroresuscitation, voluntary drug intoxication with anxiolytics - antidepressants - psychotropic drugs),
- Acute non-infectious respiratory failure, (scheduled surgery other than cardiac surgery)
- Patient hospitalized without consent,
- Patient in a period of exclusion due to another research still in progress at the time of inclusion,
- Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision,
- Pregnant, breastfeeding or parturient woman.
The study team makes the final eligibility decision.
Where it's taking place
- Trappes, France
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Trappes, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.